Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stok Raporu

Piyasa değeri: US$2.1b

Mirum Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Mirum Pharmaceuticals CEO'su Chris Peetz, Mar2019 tarihinde atandı, in görev süresi 5.67 yıldır. in toplam yıllık tazminatı $ 6.45M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.2% maaş ve 89.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.6% ine doğrudan sahiptir ve bu hisseler $ 12.62M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.7 yıl ve 4.3 yıldır.

Anahtar bilgiler

Chris Peetz

İcra Kurulu Başkanı

US$6.5m

Toplam tazminat

CEO maaş yüzdesi10.2%
CEO görev süresi5.7yrs
CEO sahipliği0.6%
Yönetim ortalama görev süresi3.7yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Nov 15
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Nov 03
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Oct 04

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 17

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Jul 13
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

May 28
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26
There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

CEO Tazminat Analizi

Chris Peetz'un ücretlendirmesi Mirum Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$109m

Mar 31 2024n/an/a

-US$159m

Dec 31 2023US$6mUS$660k

-US$163m

Sep 30 2023n/an/a

-US$164m

Jun 30 2023n/an/a

-US$176m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$4mUS$624k

-US$136m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$53m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$4mUS$600k

-US$84m

Sep 30 2021n/an/a

-US$179m

Jun 30 2021n/an/a

-US$153m

Mar 31 2021n/an/a

-US$132m

Dec 31 2020US$3mUS$512k

-US$103m

Sep 30 2020n/an/a

-US$84m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$6mUS$458k

-US$53m

Sep 30 2019n/an/a

-US$61m

Dec 31 2018US$385kUS$32k

-US$26m

Tazminat ve Piyasa: Chris 'ın toplam tazminatı ($USD 6.45M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.37M ).

Tazminat ve Kazançlar: Chris şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Chris Peetz (45 yo)

5.7yrs

Görev süresi

US$6,451,720

Tazminat

Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He also serves as Entrepreneur-in-Residence at Frazier Life Sciences Managem...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Peetz
CEO & Director5.7yrsUS$6.45m0.60%
$ 12.6m
Peter Radovich
COO & President4.6yrsUS$2.37m0.042%
$ 874.2k
Eric Bjerkholt
Chief Financial Officer1.2yrsUS$4.69m0.069%
$ 1.5m
Pamela Vig
Chief Scientific Officerless than a yearUS$1.51m0.19%
$ 4.0m
Andrew McKibben
Vice President of Investor Relations and Financeno dataVeri yokVeri yok
Paul Ross
Chief Compliance Officer4.6yrsVeri yokVeri yok
Erin Campany
Senior Vice President of Human Resources5.8yrsVeri yokVeri yok
Lara Longpre
Chief Development Officer5.9yrsUS$1.51m0.20%
$ 4.1m
Vinita Kumar
Senior vice President of Quality2.8yrsVeri yokVeri yok
Jean-Luc Girardet
Senior Vice President of Technical Operations1.8yrsVeri yokVeri yok
Joanne M. Quan
Chief Medical Officerless than a yearVeri yok0.00025%
$ 5.2k
Jolanda Howe
Senior VP & Global Controllerno dataVeri yok0.0050%
$ 105.9k

3.7yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: MIRM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Peetz
CEO & Directorno dataUS$6.45m0.60%
$ 12.6m
Patrick Heron
Independent Director6yrsUS$401.75k0%
$ 0
Laura Brege
Independent Director5.3yrsUS$426.75k0.021%
$ 436.9k
Michael Grey
Independent Non-Executive Chairman of the Board5.7yrsUS$451.75k0.58%
$ 12.2m
Laurent Fischer
Independent Director5.4yrsUS$421.75k0.014%
$ 294.9k
Timothy Walbert
Independent Director1.6yrsUS$671.53k0%
$ 0
Sona Saira Ramasastry
Independent Director2.4yrsUS$411.75kVeri yok
William Fairey
Independent Director3.3yrsUS$411.75k0%
$ 0
Lon Cardon
Independent Director2yrsUS$194.47k0%
$ 0

4.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MIRM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).